These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 24964508)
1. [Correlations between ROTEM fibrinolytic activity and t-PA, PAI-1 levels in patients with newly diagnosed multiple myeloma]. Misiewicz M; Robak M; Chojnowski K; Treliński J Pol Merkur Lekarski; 2014 May; 36(215):316-9. PubMed ID: 24964508 [TBL] [Abstract][Full Text] [Related]
2. Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis. Treliński J; Misiewicz M; Robak M; Smolewski P; Chojnowski K Thromb Res; 2014 Apr; 133(4):667-70. PubMed ID: 24451990 [TBL] [Abstract][Full Text] [Related]
3. The influence of laboratory coagulation tests and clotting factor levels on Rotation Thromboelastometry (ROTEM(R)) during major surgery with hemorrhage. Theusinger OM; Schröder CM; Eismon J; Emmert MY; Seifert B; Spahn DR; Baulig W Anesth Analg; 2013 Aug; 117(2):314-21. PubMed ID: 23780419 [TBL] [Abstract][Full Text] [Related]
4. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650 [TBL] [Abstract][Full Text] [Related]
5. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392 [TBL] [Abstract][Full Text] [Related]
6. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Siegbahn A; Ruusuvaara L Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043 [TBL] [Abstract][Full Text] [Related]
7. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion. Heubel-Moenen FCJI; Henskens YMC; Verhezen PWM; Wetzels RJH; Schouten HC; Beckers EAM J Thromb Haemost; 2019 Jul; 17(7):1073-1084. PubMed ID: 31033178 [TBL] [Abstract][Full Text] [Related]
8. Monitoring fibrinolysis in whole blood by viscoelastic instruments: a comparison of ROTEM and ReoRox. Nilsson CU; Tynngård N; Reinstrup P; Engström M Scand J Clin Lab Invest; 2013 Sep; 73(6):457-65. PubMed ID: 23767889 [TBL] [Abstract][Full Text] [Related]
9. [Activation of fibrynolysis in children with chronic B or C hepatitis]. Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691 [TBL] [Abstract][Full Text] [Related]
10. Rapid and correct prediction of thrombocytopenia and hypofibrinogenemia with rotational thromboelastometry in cardiac surgery. Olde Engberink RH; Kuiper GJ; Wetzels RJ; Nelemans PJ; Lance MD; Beckers EA; Henskens YM J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):210-6. PubMed ID: 24630470 [TBL] [Abstract][Full Text] [Related]
11. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria. Chudý P; Kotuličová D; Staško J; Kubisz P Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232 [TBL] [Abstract][Full Text] [Related]
12. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis]. Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664 [TBL] [Abstract][Full Text] [Related]
13. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states. Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814 [TBL] [Abstract][Full Text] [Related]
14. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy]. Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811 [TBL] [Abstract][Full Text] [Related]
15. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor]. Köhler M; Miyashita C Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347 [TBL] [Abstract][Full Text] [Related]
16. Fibrinolytic activity in multiple myeloma. Yağci M; Sucak GT; Haznedar R Am J Hematol; 2003 Dec; 74(4):231-7. PubMed ID: 14635202 [TBL] [Abstract][Full Text] [Related]
17. Sex differences in the determinants of fibrinolytic activity. MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046 [TBL] [Abstract][Full Text] [Related]
18. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147 [TBL] [Abstract][Full Text] [Related]
19. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity]. Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860 [TBL] [Abstract][Full Text] [Related]
20. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism. Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]